Recognizing the complexities of co‐prescriptions and life‐style factors in opioid agonist treatment: A response from Eleni Domzaridou, Matthew J. Carr, Tim Millar, Roger T. Webb and Darren M. Ashcroft

Documents similaires

• Comment on Domzaridou et al .: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment
  par: Adam Bakker, et autres
  Publié: (2024)
• Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
  par: Nadine Ezard, et autres
  Publié: (2025)
• The Opioid Safety Toolkit: An interactive prescription opioid safety toolkit to increase opioid safety literacy and behaviours among people prescribed opioids for pain—a randomised controlled trial
  par: Suzanne Nielsen, et autres
  Publié: (2026)
• Retention in opioid agonist treatment during pregnancy and variations according to treatment and maternal characteristics
  par: Bianca Varney, et autres
  Publié: (2026)
• Re: The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
  par: Yanning Wang, et autres
  Publié: (2025)